Tactile Systems Technology reports Q1 2026 results on May 6 with short sellers pulling back even as the stock slides — a disconnect that sharpens the stakes for tomorrow's print.
The short-side story is the most constructive element in the setup. Short interest has fallen 15% over the past month to 7.2% of the free float, with the bulk of that unwinding concentrated in early April when positions peaked near 1.86 million shares. That retreat is meaningful: shorts are covering into earnings rather than pressing. Borrow conditions reinforce the picture — cost to borrow is a modest 0.49%, roughly 46% above where it was a month ago but still well within normal territory, and borrow availability remains generous, suggesting no squeeze pressure in the lending market. The ORTEX short score has drifted below 49, edging further from neutral over the past two weeks.
Options positioning has turned more cautious despite the short cover. The put/call ratio climbed to 0.70, above its 20-day average of 0.59, pointing to rising demand for downside protection into the release. The move is not extreme — the z-score sits below one standard deviation — but the shift is clear: since late April, the PCR has jumped from a range around 0.45 to consistently above 0.70, a step-change in hedging activity. That caution has a price backdrop behind it: the stock has shed 9% over the past month to $22.43, underperforming most of its correlated peers. and fell roughly 5% on the week; and actually gained. TCMD's 7.5% weekly drop stands out as the more acute move in the group.
The analyst community entered this year constructively, with Piper Sandler upgrading to Overweight in January and multiple firms raising targets following the Q4 print in February — though that activity is now over two months stale and the mean target of $38 sits well above the current price of $22.43. The bull case centres on 75% gross margins, an expanding sales force, and growth in both the lymphedema and AffloVest franchises. Bears point to consecutive guidance cuts, slowing commercial uptake in the lymphedema segment, and competitive pressure in airway clearance — risks that have already driven the stock well below where analysts clustered their targets earlier this year. EPS momentum ranks in the 88th percentile on a 90-day basis and the 71st on 30-day, suggesting estimates have been revised upward even as the stock has sold off — a divergence that sets up a clear test of whether the fundamental trajectory justifies the recent repricing.
The Q1 print will determine whether the revenue deceleration story that has weighed on TCMD since late last year has finally stabilised — or whether it continues to widen the gap between where analysts expect the business to be and where the market is willing to price it.
See the live data behind this article on ORTEX.
Open TCMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
